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Osteopenia and osteoporosis are frequent in HIV
infected patients, with a prevalence of 66% and 15%
reported in a metaanalysis. In an aging population, low
bone mineral density (BMD) will translate in fracture-
related morbidity and mortality over time. As a matter
of fact, increased fracture rates in HIV positive patients
have recently been reported, particularly if older than
40-50 years. The etiology of low BMD is multifactorial.
HIV independent risk factors may thereby overweight
HIV dependent and treatment related factors. Low BMI,
malnutrition, vitamin D deficiency, substance abuse,
hypogonadism, physical inactivity or osteotoxic medica-
tion (e.g. steroids), chronic liver or kidney disease are
overrepresented in many HIV positive populations. HIV
positivity correlates with increased bone turnover. Viral
replication results in continuous cytokine production
that directly and indirectly (through RANKL) activates
osteoclasts. On the other hand, SMART and several
other studies have correlated cART initiation with accel-
erated bone loss irrespective of the regimen used.
Remarkably, this effect stabilized within the first year of
treatment and might thus be related to IRIS. Most, but
not all, associations of bone loss with protease inhibitor
treatment disappeared after correction for HIV-indepen-
dent risk factors for low BMD, in particular low BMI.
Upon Tenofovir initiation, a similar pattern has been
observed even in switch studies with suppressed viremia.
Again, these findings normalized within a year. Based on
a concomitant increase in serum alkaline phosphatase
and PTH levels, osteomalacia secondary to drug-related
renal phosphate wasting has been postulated, but lacks
strong evidence. Still, monitoring of phosphatemia and
the correction of vitamin D deficiency has been sug-
gested for Tenofovir-treated patients.
Taken together, HIV positive patients carry a relevant
risk for low-impact fractures. This merits a systematic
assessment of risk factors for low BMD and falls. Given
that a prevalent vertebral fracture indicates an equal risk
for a subsequent fracture as documented osteoporosis,
particular attention should be paid to identify subclinical
fractures. For patients aged over 40, FRAX® can be used
to identify patients qualifying for bone density measure-
ment (DXA) or biphosphonate treatment according to
national guidelines. HIV may thereby be considered as a
secondary cause of osteoporosis.
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